Suven Life Sciences Ltd has announced that the European Patent Office (EPO) has granted two patents, 1523486 and 1581538 to Suven and it is valid until June 2022.

The granted claims of the patent include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's, attention deficient hyperactivity, Huntington's disease, Parkinson and Schizophrenia.

Suven has three European patents granted until now and all of them have been validated in all the 37 member countries of Europe including major markets like Germany, Switzerland, Denmark, Spain, France, United Kingdom, Italy, Netherlands, Poland, Sweden and Finland. There are several patent applications from Suven Discovery Research are in the pipeline that have completed the administrative and technical diligence from the patent offices from major countries and would be granted shortly.

Suven has already filed its first Investigational New Drug (IND) application with DCGI to conduct the clinical Phase-I study on their developmental candidate SUVN-502 and several candidates are in discovery pipeline undergoing GLP pre-clinical studies.

We continue to work on G-Protein coupled receptor (GPCR) targets to discover and develop molecules focusing on CNS disorders with unmet medical need and high market potential, says Venkat Jasti, CEO of Suven.